Inactive Instrument

Company Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles Other stock markets
-	-

06-16	Lakefront Biotherapeutics NV commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on April 28, 2026.	CI
06-10	Lakefront Announces Share Buyback Program

Business description: Galapagos NV

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Sales by Activity: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Research and Development (R&D)	485M	505M	240M	276M	1.11B

See all business segments

Geographical breakdown of sales: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	2.11M	3.55M	16K	34.86M	-
United States of America	468M	414M	240M	241M	-

See all geographic segments

Executive Committee: Galapagos NV

Manager	Title	Age	Since
Henry Gosebruch CEO	Chief Executive Officer	53	2025-05-12
Aaron Cox DFI	Director of Finance/CFO	43	2025-07-06
Eric Hedrick CTO	Chief Tech/Sci/R&D Officer	61	2026-06-07
Robert Hughes CTO	Chief Tech/Sci/R&D Officer	-	2023-12-31
Sandra Cauwenberghs IRC	Investor Relations Contact	-	2020-10-31

See GALAPAGOS NV governance

Composition of the Board of Directors: Galapagos NV

Director	Title	Age	Since
Linda Higgins BRD	Director/Board Member	63	2019-10-21
Oleg Nodelman BRD	Director/Board Member	49	2024-10-06
Henry Gosebruch BRD	Director/Board Member	53	2025-05-12
Dawn Svoronos BRD	Director/Board Member	72	2025-07-27
Jane Griffiths BRD	Director/Board Member	71	2025-07-27
Neil G. Johnston BRD	Director/Board Member	-	2025-10-31
Devang Bhuva BRD	Director/Board Member	-	2025-10-31
Paulo Fontoura BRD	Director/Board Member	-	2026-02-08
Gino Santini CHM	Chairman	69	2026-04-27

Composition of the Board of Directors

Shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	477 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	205 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	132 M
Saint Olive Gestion SNC 0.0645 %	42,500	0.0645 %	1 M
Zenito Oy 0.0493 %	32,500	0.0493 %	927 667

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	474 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	107 M
Madison Avenue Partners LP 5.472 %	3,606,203	5.472 %	102 M
Madison Avenue Partners LP 3.741 %	2,465,179	3.741 %	70 M
EcoR1 Capital, LLC 2.53 %	1,667,119	2.53 %	47 M

List of GALAPAGOS NV shareholders

Company details: Galapagos NV

Galapagos NV

Industriepark Mechelen Noord

2800, Mechelen

+32 1 534 29 00

http://www.galapagos.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	49.15B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	25.19B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	13.83B
ICON PUBLIC LIMITED COMPANY	-1.14%	+1.88%	+15.30%	-28.79%	13.26B
Average	+1.68%	+5.91%	+70.55%	+104.31%	26.92B
Weighted average by Cap.	+1.81%	+6.27%	+87.46%	+131.74%